{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:52:22Z","timestamp":1792450342586,"version":"4.5.0"},"reference-count":89,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mastocytosis is a type of myeloid neoplasm characterized by the clonal, neoplastic proliferation of morphologically and immunophenotypically abnormal mast cells that infiltrate one or more organ systems. Systemic mastocytosis (SM) is a more aggressive variant of mastocytosis with extracutaneous involvement, which might be associated with multi-organ dysfunction or failure and shortened survival. Over 80% of patients with SM carry the KIT D816V mutation. However, the KIT D816V mutation serves as a weak oncogene and appears to be a late event in the pathogenesis of mastocytosis. The management of SM is highly individualized and was largely palliative for patients without a targeted form of therapy in past decades. Targeted therapy with midostaurin, a multiple kinase inhibitor that inhibits KIT, has demonstrated efficacy in patients with advanced SM. This led to the recent approval of midostaurin by the United States Food and Drug Administration and European Medicines Agency. However, the overall survival of patients treated with midostaurin remains unsatisfactory. The identification of genetic and epigenetic alterations and understanding their interactions and the molecular mechanisms involved in mastocytosis is necessary to develop rationally targeted therapeutic strategies. This review briefly summarizes recent developments in the understanding of SM pathogenesis and potential treatment strategies for patients with SM.<\/jats:p>","DOI":"10.3390\/ijms22094900","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T22:51:42Z","timestamp":1620255102000},"page":"4900","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New Insights into the Pathogenesis of Systemic Mastocytosis"],"prefix":"10.3390","volume":"22","author":[{"given":"Zhixiong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMra1409760","article-title":"Mast Cells, Mastocytosis, and Related Disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","article-title":"Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Pardanani","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: Analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gotlib, J., Kluin-Nelemans, H.C., Akin, C., Hartmann, K., Valent, P., and Reiter, A. (2021). Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin. Biol., 1\u201312.","DOI":"10.1080\/14712598.2021.1837109"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"(2018). Rapid Responses to Avapritinib (BLU-285) in Mastocytosis. Cancer Discov., 8, 133.","DOI":"10.1158\/2159-8290.CD-NB2017-177"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.24673","article-title":"Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia","volume":"92","author":"Ustun","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/thno.51872","article-title":"Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis","volume":"11","author":"Jawhar","year":"2021","journal-title":"Theranostics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Teodosio","year":"2006","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","article-title":"Mastocytosis Centre Odense University, H. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis","volume":"132","author":"Kristensen","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/MCB.01153-06","article-title":"Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling","volume":"27","author":"Xiang","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20050807","article-title":"Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation","volume":"202","author":"Zappulla","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/aoms.2012.29534","article-title":"Mastocytosis in children and adults: Clinical disease heterogeneity","volume":"8","author":"Lange","year":"2012","journal-title":"Arch. Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Saleh","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.4049\/jimmunol.180.8.5466","article-title":"Unique effects of KIT D816V in BaF3 cells: Induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens","volume":"180","author":"Mayerhofer","year":"2008","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjh.12999","article-title":"A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis","volume":"167","author":"Balci","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood-2008-11-189605","article-title":"Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit","volume":"117","author":"Gerbaulet","year":"2011","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V88.3.995.995","article-title":"Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase","volume":"88","author":"Kitayama","year":"1996","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73871","DOI":"10.18632\/oncotarget.18027","article-title":"Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1182\/blood-2008-05-155200","article-title":"High-affinity neurotrophin receptors and ligands promote leukemogenesis","volume":"113","author":"Li","year":"2009","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1042\/CS20160044","article-title":"Neurotrophin signalling: Novel insights into mechanisms and pathophysiology","volume":"131","author":"Mitre","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/nature02765","article-title":"Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB","volume":"430","author":"Douma","year":"2004","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","article-title":"TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations","volume":"26","author":"Rosen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood-2014-03-560466","article-title":"Activation of TRKB receptor in murine hematopoietic stem\/progenitor cells induced mastocytosis","volume":"124","author":"Yang","year":"2014","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.1068893","article-title":"Murine leukemia induced by retroviral gene marking","volume":"296","author":"Li","year":"2002","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/sj.leu.2404882","article-title":"Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA","volume":"21","author":"Meyer","year":"2007","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2012-12-469882","article-title":"Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis","volume":"122","author":"Peng","year":"2013","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/emboj\/19.8.1827","article-title":"Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia","volume":"19","author":"Liu","year":"2000","journal-title":"Embo. J."},{"key":"ref_42","first-page":"310","article-title":"Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1)","volume":"94","author":"Welker","year":"1998","journal-title":"Immunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood.V95.6.2052","article-title":"Nerve growth factor functions as a chemoattractant for mast cells through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways","volume":"95","author":"Sawada","year":"2000","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/IR:34:2:97","article-title":"Development, migration, and survival of mast cells","volume":"34","author":"Okayama","year":"2006","journal-title":"Immunol Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1046\/j.1365-2222.2000.00866.x","article-title":"Nerve growth factor prevents apoptosis of cord blood-derived human cultured mast cells synergistically with stem cell factor","volume":"30","author":"Kanbe","year":"2000","journal-title":"Clin. Exp. Allergy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"31707","DOI":"10.1074\/jbc.M111.233486","article-title":"Human tryptase cleaves pro-nerve growth factor (pro-NGF): Hints of local, mast cell-dependent regulation of NGF\/pro-NGF action","volume":"286","author":"Spinnler","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Skaper, S.D. (2017). Nerve growth factor: A neuroimmune crosstalk mediator for all seasons. Immunology, 151.","DOI":"10.1111\/imm.12717"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1034\/j.1398-9995.1999.00204.x","article-title":"Nerve growth factor release with mast-cell-derived mediators in a patient with systemic mastocytosis after middle-wave ultraviolet irradiation","volume":"54","author":"Kurosawa","year":"1999","journal-title":"Allergy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2982.2007.00899.x","article-title":"Neurotrophin-3, but not nerve growth factor, promotes survival of human intestinal mast cells","volume":"19","author":"Lorentz","year":"2007","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1182\/blood-2011-06-359984","article-title":"mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells","volume":"118","author":"Smrz","year":"2011","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1172\/JCI62279","article-title":"mTORC1 is essential for leukemia propagation but not stem cell self-renewal","volume":"122","author":"Hoshii","year":"2012","journal-title":"J. Clin. Invest."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.stem.2012.05.026","article-title":"Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression","volume":"11","author":"Magee","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/leu.2016.223","article-title":"Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia","volume":"31","author":"Fang","year":"2017","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20111470","article-title":"Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia","volume":"209","author":"Lee","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/10428190903486220","article-title":"Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis","volume":"51","author":"Parikh","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells","volume":"108","author":"Lepelletier","year":"2006","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.4049\/jimmunol.180.7.4586","article-title":"Activation and function of the mTORC1 pathway in mast cells","volume":"180","author":"Kim","year":"2008","journal-title":"J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood-2012-12-476200","article-title":"Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis","volume":"121","author":"Chan","year":"2013","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1172\/JCI66167","article-title":"Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk","volume":"123","author":"Staser","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1398-9995.2010.02477.x","article-title":"Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis","volume":"66","author":"Niedoszytko","year":"2011","journal-title":"Allergy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1084\/jem.20171151","article-title":"Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation","volume":"215","author":"Nagase","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"De Vita, S., Schneider, R.K., Garcia, M., Wood, J., Gavillet, M., Ebert, B.L., Gerbaulet, A., Roers, A., Levine, R.L., and Mullally, A. (2014). Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096209"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/leu.2017.183","article-title":"SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis","volume":"32","author":"Martinelli","year":"2018","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Tsutsumi, M., Miura, H., Inagaki, H., Shinkai, Y., Kato, A., Kato, T., Hamada-Tsutsumi, S., Tanaka, M., Kudo, K., and Yoshikawa, T. (2020). An aggressive systemic mastocytosis preceded by ovarian dysgerminoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07653-z"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11408","DOI":"10.1073\/pnas.0504197102","article-title":"Identification of mast cell progenitors in adult mice","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41379-019-0447-x","article-title":"Detection of the KIT(D816V) mutation in myelodysplastic and\/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis","volume":"33","author":"Craig","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2019.03.089","article-title":"Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis","volume":"43","author":"Grootens","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ejh.13528","article-title":"Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle","volume":"106","author":"Hagglund","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_77","first-page":"2183","article-title":"CAR T cell therapy: A new era for cancer treatment (Review)","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/leu.2015.16","article-title":"Aberrant expression of CD123 (interleukin-3 receptor-alpha) on neoplastic mast cells","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.16288","article-title":"The clinical and pathological panoply of systemic mastocytosis","volume":"188","author":"Radia","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood.2019004509","article-title":"Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis","volume":"137","author":"Toledo","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): A retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: A retrospective prognostic modelling study","volume":"8","author":"Zanotti","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Henriques","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Giannetti, M.P., Weller, E., Alvarez-Twose, I., Torrado, I., Bonadonna, P., Zanotti, R., Dwyer, D.F., Foer, D., Akin, C., and Hartmann, K. (2021). COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J. Allergy Clin. Immunol.","DOI":"10.1016\/j.jaip.2021.02.023"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2021.01.004","article-title":"mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis","volume":"147","author":"Rama","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4900\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:57:25Z","timestamp":1760162245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":89,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22094900"],"URL":"https:\/\/doi.org\/10.3390\/ijms22094900","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]}}}